Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 5/20 | 0.48 |
| ▸ | MMP1 | P03956 | 4/20 | 0.48 |
| ▸ | MMP2 | P08253 | 4/20 | 0.48 |
| ▸ | MMP8 | P22894 | 4/20 | 0.48 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.45 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.45 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.45 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.45 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.45 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13167423 | 1.00 | MMP9 (0.48) | MMP9MMP1MMP2MMP8PSEN1 | |
| SCHEMBL21843955 | 1.00 | MMP9 (0.48) | MMP9MMP1MMP2MMP8PSEN1 | |
| SCHEMBL20131094 | 1.00 | MMP9 (0.48) | MMP9MMP1MMP2MMP8PSEN1 | |
| SCHEMBL14017828 | 1.00 | MMP9 (0.48) | MMP9MMP1MMP2MMP8PSEN1 | |
| SCHEMBL13039794 | 1.00 | MMP9 (0.48) | MMP9MMP1MMP2MMP8PSEN1 | |
| SCHEMBL20131063 | 0.84 | MMP9 (0.47) | MMP9MMP1MMP2MMP8PSEN1 | |
| SCHEMBL24946114 | 0.83 | MMP9 (0.43) | MMP9MMP1MMP2MMP8PSEN1 | |
| SCHEMBL18893525 | 0.82 | MMP9 (0.46) | MMP9MMP1MMP2MMP8PSEN1 | |
| SCHEMBL18893378 | 0.82 | MMP9 (0.46) | MMP9MMP1MMP2MMP8PSEN1 | |
| SCHEMBL12380788 | 0.81 | OPRM1 (0.41) | MMP9MMP1MMP2MMP8MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062975-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | SPRING MILL PHARMA, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11014881-B2 | Hepatitis B capsid assembly modulators | VenatoRx Pharmaceuticals, Inc. (US) | 2021-05-25 | — | — | US | disclosed |
| US-10995064-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2021-05-04 | — | — | US | disclosed |
| US-10676429-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2020-06-09 | — | — | US | disclosed |
| US-20200123105-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | SPRING MILL PHARMA, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARAMCEUTICALS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180127361-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-05-10 | — | — | US | disclosed |
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | OSI PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | OSI PHARMACEUTICALS, INC. | 2009-07-30 | — | — | US | disclosed |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | disclosed |
| US-7504407-B2 | Compounds specific to adenosine A1 and A3 receptors and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7429574-B2 | 4-heterocyclo-pyrrolo[2,3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | OSI PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-7253165-B2 | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2007-08-07 | — | — | US | disclosed |
| US-7160890-B2 | Compounds specific to adenosine A3 receptor and uses thereof | OSI PHARMACEUTICALS, INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6680324-B2 | 4-AMINO-6-PHENYL-PYRROLO(2,3-D)PYRIMIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2004-01-20 | — | — | US | disclosed |
| EP-0860439-B1 | Process for preparing an optically active phenylglycidyl acid derivative | DSM NV (NL) | 2001-06-13 | — | — | EP | disclosed |
| US-6025506-A | Process for preparing an optically active phenylglycidyl acid derivative | DSM N.V. (NL) | 2000-02-15 | — | — | US | disclosed |
| EP-0860439-A1 | Process for preparing an optically active phenylglycidyl acid derivative | DSM N.V. (NL) | 1998-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676429-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | SULT2A1, HCCS, SULT1A1 | MMP9 3479/4885MMP1 4210/4885MMP2 3231/4885 |
| US-20200123105-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | MMP9 4251/4885MMP1 4823/4885MMP2 4063/4885 |
| US-20090192177-A1 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors | ADORA3, ADORA1, ADORA2A | MMP9 4613/4885MMP1 4400/4885MMP2 4540/4885 |
| US-20230062975-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | HAVCR2, COPB1, HDLBP | MMP9 4251/4885MMP1 4823/4885MMP2 4063/4885 |
| US-20180127361-A1 | SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | SULT2A1, HCCS, SULT1A1 | MMP9 3479/4885MMP1 4210/4885MMP2 3231/4885 |
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | MMP9 405/4885MMP1 319/4885MMP2 74/4885 |
| US-20090082369-A1 | Pyrrolo[2,3d]pyrimidine compositions and their use | ADORA3, ADORA2A, ADORA1 | MMP9 4506/4885MMP1 4425/4885MMP2 4784/4885 |
| US-20080070936-A1 | Compounds specific to adenosine A1 receptors and uses thereof | ADORA1, ADORA2A, ADORA3 | MMP9 3577/4885MMP1 2812/4885MMP2 3418/4885 |
| US-11014881-B2 | Hepatitis B capsid assembly modulators | HAVCR2, COPB1, HDLBP | MMP9 4251/4885MMP1 4823/4885MMP2 4063/4885 |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | MMP9 1765/4885MMP1 2619/4885MMP2 1726/4885 |
| US-10995064-B2 | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B | SULT2A1, HCCS, SULT1A1 | MMP9 3479/4885MMP1 4210/4885MMP2 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.